Literature DB >> 18997484

Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population.

M Erdogan1, M Karadeniz, M Ozbek, A G Ozgen, A Berdeli.   

Abstract

OBJECTIVE: Interleukin-10 (IL-10) is a major anti-inflammatory cytokine that plays a crucial role in the regulation of the immune system. Chronic inflammation has been reported to be a risk factor for thyroid neoplasia. The propensity to mount an inflammatory response is modified by germ line variation in cytokine and other inflammation-related genes. We hypothesized that a proinflammatory genotype would be positively associated with thyroid cancer. We aimed to evaluate the relation between the genotypic and allelic frequencies of the IL-10(-1082 G/A), IL-10(-592 A/C), and IL-10(-819 C/T) polymorphisms, and their association with the risk of developing papillary thyroid cancer (PTC) in the Turkish population. RESEARCH DESIGN AND METHODS: Forty-two patients with PTC and 113 healthy controls were included in this study. The diagnosis of PTC was confirmed by histopathologic examination after surgery. The evaluation of genotype for IL-10 gene polymorphism was performed using PCR-restriction fragment length polymorphism method.
RESULTS: Statistically significant difference IL-10(-1082 G/A) gene polymorphism was determined between 2 (PTC and control) groups. No difference was determined with respect to IL-10(-592 A/C) and IL-10(-819 C/T) gene polymorphisms, and IL-10(-1082 G/A), IL-10(-592 A/C), and IL-10(-819 C/T) allele frequencies of participating between the control group and the patients with PTC (p>0.05).
CONCLUSIONS: The polymorphism of IL-10(-1082 G/A) gene was significantly associated with the occurrence of PTC. Such studies will contribute significantly to our understanding of the biological role of IL-10(-1082 G/A) gene polymorphism in PTC development. In conclusion, IL-10(-1082 G/A) gene polymorphism may affect the survival of papillary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997484     DOI: 10.1007/BF03349252

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

1.  An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma.

Authors:  E Havranek; W M Howell; H M Fussell; J A Whelan; M A Whelan; H S Pandha
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

2.  Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma.

Authors:  L M Cunningham; C Chapman; R Dunstan; M C Bell; D J L Joske
Journal:  Leuk Lymphoma       Date:  2003-02

Review 3.  Molecular classification and biomarker discovery in papillary thyroid carcinoma.

Authors:  Orla Sheils
Journal:  Expert Rev Mol Diagn       Date:  2005-11       Impact factor: 5.225

4.  Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study.

Authors:  Tanja Eder; Ramona Mayer; Uwe Langsenlehner; Wilfried Renner; Peter Krippl; Thomas C Wascher; Karl Pummer; Karin S Kapp
Journal:  Eur J Cancer       Date:  2006-12-19       Impact factor: 9.162

5.  Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation.

Authors:  Christy M Caudill; Zhaowen Zhu; Raffaele Ciampi; James R Stringer; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2005-01-25       Impact factor: 5.958

6.  IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma.

Authors:  Grzegorz Mazur; Katarzyna Bogunia-Kubik; Tomasz Wróbel; Lidia Karabon; Małgorzata Polak; Kazimierz Kuliczkowski; Andrzej Lange
Journal:  Immunol Lett       Date:  2005-01-31       Impact factor: 3.685

7.  Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation.

Authors:  Eric Alamartine; Patricia Berthoux; Christophe Mariat; Frédéric Cambazard; François Berthoux
Journal:  J Invest Dermatol       Date:  2003-01       Impact factor: 8.551

8.  Interleukin-10 promoter polymorphisms in patients with hepatitis B virus infection or hepatocellular carcinoma in Chinese Han ethnic population.

Authors:  Juan Wang; Hong Ni; Li Chen; Wen-Qin Song
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2006-02

9.  Polymorphisms in interleukin -2, -6, and -10 are not associated with gastric cardia or esophageal cancer in a high-risk chinese population.

Authors:  Sharon A Savage; Christian C Abnet; Kashif Haque; Steven D Mark; You-Lin Qiao; Zhi-Wei Dong; Sanford M Dawsey; Philip R Taylor; Stephen J Chanock
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-09       Impact factor: 4.254

10.  TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer.

Authors:  Carola Seifart; Alexandra Plagens; Astrid Dempfle; Ursula Clostermann; Claus Vogelmeier; Peter von Wichert; Ulf Seifart
Journal:  Dis Markers       Date:  2005       Impact factor: 3.434

View more
  12 in total

1.  Interleukins as markers of inflammation in malignant and benign thyroid disease.

Authors:  Xeni Provatopoulou; Despoina Georgiadou; Theodoros N Sergentanis; Eleni Kalogera; John Spyridakis; Antonia Gounaris; George N Zografos
Journal:  Inflamm Res       Date:  2014-05-03       Impact factor: 4.575

2.  Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer.

Authors:  Esra Çil; Alkın Kumral; Müge Kanmaz-Özer; Pervin Vural; Semra Doğru-Abbasoğlu; Yüksel Altuntaş; Müjdat Uysal
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

3.  siRNA-mediated downregulation of TC21 sensitizes esophageal cancer cells to cisplatin.

Authors:  Raghibul Hasan; Shyam Singh Chauhan; Rinu Sharma; Ranju Ralhan
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

4.  Association of IL-10-1082 promoter polymorphism with susceptibility to gastric cancer: evidence from 22 case-control studies.

Authors:  Feng Pan; Jing Tian; Yue-Yin Pan; Ying Zhang
Journal:  Mol Biol Rep       Date:  2012-02-05       Impact factor: 2.316

5.  The interleukin-10 promoter polymorphism rs1800872 (-592C>A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls.

Authors:  Qi Ding; Ying Shi; Bo Fan; Zhijiang Fan; Li Ding; Feng Li; Wenjian Tu; Xiaohua Jin; Jing Wang
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

6.  A Polymorphism (rs1801018, Thr7Thr) of BCL2 is Associated with Papillary Thyroid Cancer in Korean Population.

Authors:  Young Gyu Eun; Il Ki Hong; Su Kang Kim; Hyun-Kyung Park; Sam Kwon; Dae Han Chung; Kee Hwan Kwon
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-09-06       Impact factor: 3.372

7.  Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer.

Authors:  Lucas Leite Cunha; Alfio Jose Tincani; Ligia Vera Montalli da Assumpção; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  A missense polymorphism (rs11895564, Ala380Thr) of integrin alpha 6 is associated with the development and progression of papillary thyroid carcinoma in Korean population.

Authors:  Su Kang Kim; Dong Kwan Kim; In-Hwan Oh; Jeong Yoon Song; Kee Hwan Kwon; Bong-Keun Choe; Yong Ho Kim
Journal:  J Korean Surg Soc       Date:  2011-11-01

9.  Association of interleukin-10 promoter polymorphisms and corresponding plasma levels with susceptibility to laryngeal squamous cell carcinoma.

Authors:  Jian Zhou; Duo Zhang; Bin Chen; Qing Li; Lin Zhou; Fei Liu; Kuang-Yen Chou; Lei Tao; Li-Ming Lu
Journal:  Oncol Lett       Date:  2014-02-26       Impact factor: 2.967

10.  Association of Inflammation-Related Gene Polymorphisms With Susceptibility and Radiotherapy Sensitivity in Head and Neck Squamous Cell Carcinoma Patients in Northeast China.

Authors:  Ying Li; Li Zhu; Hongmin Yao; Ye Zhang; Xiangyu Kong; Liping Chen; Yingqiu Song; Anna Mu; Xia Li
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.